SFM
RARE icon

Systematic Financial Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Systematic Financial Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,668
Closed -$107K – 292
2023
Q1 		$107K Buy
+2,668
New +$114K ﹤0.01% 278

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Systematic Financial Management's RARE Position: Q2 2023 in Review

Systematic Financial Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2023, closing a stake of 2,668 shares — an estimated $107K sold.

Systematic Financial Management first reported a position in RARE in Q1 2023 and held it in 1 quarter. The position peaked at $107K in Q1 2023. 242 funds tracked by Wall St. Rank hold RARE as of Q2 2023.

  • Systematic Financial Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2023 after selling out during the quarter.
  • Systematic Financial Management sold 2,668 Ultragenyx Pharmaceutical shares in Q2 2023, an estimated $107K.
  • Systematic Financial Management first reported a position in Ultragenyx Pharmaceutical in Q1 2023 and held it in 1 quarter.
  • Systematic Financial Management's Ultragenyx Pharmaceutical position peaked at $107K in Q1 2023.
  • 242 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2023.

Based on Systematic Financial Management's 13F filing for Q2 2023, filed 14 Aug 2023.